Jump to content
helplinedonate
Suzita

Statins and PD

Recommended Posts

Hello, 

I am a 72 year old female. My mother suffered from Parkinsons and my first cousin had supranuclear palsy. I have read there may be some risk involved in taking statin drugs if you have a family history of Parkinson's. I have resisted taking statins for 10 years. I am sure my doctor is going to start getting insistent about taking the meds. Can you tell me if it would be wiser of me to seek more natural remedy for the elevated cholesterol? I do not have a history of heart disease in my family and have had a heart scan done with zero calcium accumlation. Thank you.

Share this post


Link to post
Share on other sites

This is a controversial area and Dr. Huang at Penn State Hershey is an expert.  If you already have PD then taking drugs for cholesterol is not controversial.  If you don't have PD there is argument about epidemiological risk and recently the lipid profile.  You may want to reach out to Dr. Huang for her latest research.  Below is one of her articles.

 
Front Neurol. 2017 Sep 27;8:501. doi: 10.3389/fneur.2017.00501. eCollection 2017.

Circulating Cholesterol Levels May Link to the Factors Influencing Parkinson's Risk.

Abstract

OBJECTIVES:

A growing literature suggests that circulating cholesterol levels have been associated with Parkinson's disease (PD). In this study, we investigated a possible causal basis for the cholesterol-PD link.

METHODS:

Fasting plasma cholesterol levels were obtained from 91 PD and 70 age- and gender-matched controls from an NINDS PD Biomarkers Program cohort at the Pennsylvania State University College of Medicine. Based on the literature, genetic polymorphisms in selected cholesterol management genes (APOE, LDLR, LRP1, and LRPAP1) were chosen as confounding variables because they may influence both cholesterol levels and PD risk. First, the marginal structure model was applied, where the associations of total- and LDL-cholesterol levels with genetic polymorphisms, statin usage, and smoking history were estimated using linear regression. Then, potential causal influences of total- and LDL-cholesterol on PD occurrence were investigated using a generalized propensity score approach in the second step.

RESULTS:

Both statins (p < 0.001) and LRP1 (p < 0.03) influenced total- and LDL-cholesterol levels. There also was a trend for APOE to affect total- and LDL-cholesterol (p = 0.08 for both), and for LRPAR1 to affect LDL-cholesterol (p = 0.05). Conversely, LDLR did not influence plasma cholesterol levels (p > 0.19). Based on propensity score methods, lower total- and LDL-cholesterol were significantly linked to PD (p < 0.001 and p = 0.04, respectively).

CONCLUSION:

The current study suggests that circulating total- and LDL-cholesterol levels potentially may be linked to the factor(s) influencing PD risk. Further studies to validate these results would impact our understanding of the role of cholesterol as a risk factor in PD, and its relationship to recent public health controversies.

KEYWORDS:

Parkinson’s disease; cholesterol; genetics; propensity score; statins

PMID:
29021777
PMCID:
PMC5624032
DOI:
10.3389/fneur.2017.00501
 

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×